These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 27456338)
21. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. Han SK; Mytilineou C; Cohen G J Neurochem; 1996 Feb; 66(2):501-10. PubMed ID: 8592119 [TBL] [Abstract][Full Text] [Related]
22. Region-Specific Neuroprotective Features of Astrocytes against Oxidative Stress Induced by 6-Hydroxydopamine. Asanuma M; Okumura-Torigoe N; Miyazaki I; Murakami S; Kitamura Y; Sendo T Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704073 [TBL] [Abstract][Full Text] [Related]
23. Conditioned place preference induced by a combination of L-dopa and a COMT inhibitor, entacapone, in rats. Katajamäki J; Honkanen A; Piepponen TP; Lindén IB; Zharkovsky A; Ahtee L Pharmacol Biochem Behav; 1998 May; 60(1):23-6. PubMed ID: 9610919 [TBL] [Abstract][Full Text] [Related]
24. Yokukansan, a Traditional Japanese Medicine, Enhances the L-DOPA-Induced Rotational Response in 6-Hydroxydopamine-Lesioned Rats: Possible Inhibition of COMT. Ishida Y; Ebihara K; Tabuchi M; Imamura S; Sekiguchi K; Mizoguchi K; Kase Y; Koganemaru G; Abe H; Ikarashi Y Biol Pharm Bull; 2016; 39(1):104-13. PubMed ID: 26725433 [TBL] [Abstract][Full Text] [Related]
25. 3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats. Bräutigam K; Sohr R; Morgenstern R Behav Brain Res; 1994 Jul; 63(1):41-5. PubMed ID: 7945976 [TBL] [Abstract][Full Text] [Related]
26. Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats. Qi Q; Cao L; Li F; Wang H; Liu H; Hao H; Hao K Xenobiotica; 2015; 45(9):820-7. PubMed ID: 25869243 [TBL] [Abstract][Full Text] [Related]
27. The role of 3-O-methyldopa in the side effects of L-dopa. Lee ES; Chen H; King J; Charlton C Neurochem Res; 2008 Mar; 33(3):401-11. PubMed ID: 17713853 [TBL] [Abstract][Full Text] [Related]
28. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. Mena MA; Davila V; Sulzer D J Neurochem; 1997 Oct; 69(4):1398-408. PubMed ID: 9326268 [TBL] [Abstract][Full Text] [Related]
29. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558 [TBL] [Abstract][Full Text] [Related]
30. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone). Soares-da-Silva P; Vieira-Coelho MA; Parada A Pharmacol Toxicol; 2003 Jun; 92(6):272-8. PubMed ID: 12787259 [TBL] [Abstract][Full Text] [Related]
31. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase. Engelbrecht I; Petzer JP; Petzer A Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034 [TBL] [Abstract][Full Text] [Related]
32. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346 [TBL] [Abstract][Full Text] [Related]
33. Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection. Kikuoka R; Miyazaki I; Kubota N; Maeda M; Kagawa D; Moriyama M; Sato A; Murakami S; Kitamura Y; Sendo T; Asanuma M Sci Rep; 2020 Nov; 10(1):20698. PubMed ID: 33244123 [TBL] [Abstract][Full Text] [Related]
34. Establishing the probable mechanism of L-DOPA in Alzheimer's disease management. Nivsarkar M; Banerjee A Acta Pol Pharm; 2009; 66(5):483-6. PubMed ID: 19894644 [TBL] [Abstract][Full Text] [Related]
35. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Zubair M; Jackson MJ; Tayarani-Binazir K; Stockwell KA; Smith LA; Rose S; Olanow W; Jenner P Exp Neurol; 2007 Dec; 208(2):177-84. PubMed ID: 17935716 [TBL] [Abstract][Full Text] [Related]
36. L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. Espadas I; Darmopil S; Vergaño-Vera E; Ortiz O; Oliva I; Vicario-Abejón C; Martín ED; Moratalla R Neurobiol Dis; 2012 Dec; 48(3):271-81. PubMed ID: 22820144 [TBL] [Abstract][Full Text] [Related]
37. Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa. Reches A; Jiang D; Fahn S Naunyn Schmiedebergs Arch Pharmacol; 1982 Jul; 320(1):34-7. PubMed ID: 7121609 [TBL] [Abstract][Full Text] [Related]
38. Striatal astrocytes act as a reservoir for L-DOPA. Asanuma M; Miyazaki I; Murakami S; Diaz-Corrales FJ; Ogawa N PLoS One; 2014; 9(9):e106362. PubMed ID: 25188235 [TBL] [Abstract][Full Text] [Related]
39. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway. Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099 [TBL] [Abstract][Full Text] [Related]
40. Cyclooxygenase-independent neuroprotective effects of aspirin against dopamine quinone-induced neurotoxicity. Asanuma M; Miyazaki I; Kikkawa Y; Kimoto N; Takeshima M; Murakami S; Miyoshi K Neurochem Res; 2012 Sep; 37(9):1944-51. PubMed ID: 22674083 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]